证券时报·数据宝统计显示，以发行日期为基准统计，截至12月15日，今年以来科创板累计有17家公司 发行新股，累计募资金额达350.89亿元，单家公司平均募集资金20.64亿元。分区间来看，募资金额超10 亿元的有12家，募资金额5亿元至10亿元的有4家，募资金额在5亿元以下的有1家。 摩尔线程为今年以来募资金额最多的科创板公司，首发募集资金达80.00亿元，募资主要投向使用部分 闲置募集资金进行现金管理，摩尔线程新一代自主可控AI训推一体芯片研发项目，摩尔线程新一代自 主可控图形芯片研发项目等；其次是西安奕材，募资金额为46.36亿元，募资主要用于西安奕斯伟硅产 业基地二期项目，使用部分募集资金进行现金管理等。募资金额较多的还有沐曦股份、禾元生物、屹唐 股份等，分别募资41.97亿元、25.99亿元、24.97亿元。 发行价格方面，今年已发行的科创板股平均首发价格为36.56元，发行价在50元以上的有4家，其中，发 行价超百元的有2家，发行价最高的是摩尔线程，发行价为114.28元，沐曦股份、昂瑞微次之，发行价 分别为104.66元、83.06元，发行价较低的有屹唐股份、西安奕材等，首发价格分别为8.45元、 ...

Core Points - Hanbang Technology's stock price decreased by 1.76% on November 17, with a trading volume of 42.3962 million yuan [1] - The company recorded a net financing purchase of 1.1831 million yuan on the same day, with a total financing balance of 80.224 million yuan, accounting for 10.58% of its market capitalization [1] - As of September 30, the company achieved a revenue of 506 million yuan, representing a year-on-year growth of 4.61%, while the net profit attributable to shareholders decreased by 17.27% to 37.0172 million yuan [2] Financing and Trading Data - On November 17, Hanbang Technology had a financing buy amount of 2.7984 million yuan and a financing repayment of 1.6154 million yuan [1] - The company had no short selling activity on November 17, with a short selling balance of 0 [1] - The total number of shareholders as of September 30 was 8,687, a decrease of 7.31% from the previous period [2] Business Overview - Hanbang Technology, established on October 28, 1998, specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of the company includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] - The company has distributed a total of 8.8 million yuan in dividends since its A-share listing [3]

Group 1 - The company, Hanbang Technology (688755.SH), focuses on small molecule liquid chromatography and large molecule chromatography equipment primarily used in the biopharmaceutical field, including the development and production of antibodies, recombinant proteins, vaccines, insulin, and peptides [1] - The company emphasizes technology research and development as its core, aiming to provide customers with integrated solutions of "equipment + consumables + process development" to support key technological breakthroughs in the biomanufacturing sector [1] Group 2 - An investor inquired about the company's separation and purification equipment used in biomanufacturing and whether its current R&D projects involve key technological breakthroughs in this field, as highlighted in the 14th Five-Year Plan [3]

Core Insights - The report highlights the IPO activities in Jiangsu province for October 2025, indicating a stable trend with 9 new A-share companies listed, similar to previous months [1][10]. Group 1: IPO Overview - In October 2025, Jiangsu saw the listing of 1 new company, Changjiang Energy Materials, on the Beijing Stock Exchange, with a fundraising amount of 1.84 billion [2][10]. - For the first ten months of 2025, Jiangsu ranked first among provinces with 21 new A-share companies, surpassing Guangdong by 4 companies [10][17]. - The total fundraising amount for Jiangsu's IPOs in the first ten months reached 129.27 billion, placing it third nationally [17][29]. Group 2: City-wise IPO Distribution - Suzhou led the province with 7 new A-share companies in the first ten months, followed by Wuxi and Changzhou with 3 each [10][17]. - The distribution of new A-share companies by city in October 2025 shows that Jiangsu's cities are actively participating in the IPO market, with various cities contributing to the overall count [5][10]. Group 3: Fundraising Analysis - The total fundraising for Jiangsu's IPOs in October was relatively low at 1.84 billion, indicating a need for more robust fundraising activities [17]. - Suzhou's total fundraising amount for the first ten months was 57.48 billion, maintaining its position as the top city in Jiangsu for IPO fundraising [17][13]. Group 4: Sector and Board Distribution - The newly listed companies in Jiangsu for the first ten months were distributed across four boards, with the Growth Enterprise Market (GEM) having the highest number at 7 companies [17][11]. - The breakdown of the newly listed companies by board shows a diverse participation across different sectors, reflecting the province's economic landscape [11][17]. Group 5: IPO Pipeline and Support - As of the end of October, there were 301 companies in the IPO application queue nationwide, with Jiangsu having 51, ranking third in the country [29]. - Jiangsu also leads in the number of companies undergoing IPO guidance, with 243 firms, indicating a strong support system for potential IPO candidates [29][26].

Core Viewpoint - Hanbang Technology announced that its first public offering of offline placement restricted shares, totaling 1,059,253 shares, will be listed for circulation on November 17, 2025, representing 1.20% of the company's total share capital [1] Summary by Category - **Company Announcement** - Hanbang Technology will list 1,059,253 shares for circulation on November 17, 2025 [1] - The shares represent 1.20% of the total share capital of the company [1]

Core Points - The announcement pertains to the listing and circulation of restricted shares for Jiangsu Hanbang Technology Co., Ltd. [1] - The total number of shares to be listed is 1,059,253, which represents 1.20% of the company's total share capital [2][9] - The listing date for these restricted shares is set for November 17, 2025 [4][9] Group 1: Share Issuance Details - The shares being listed are part of the company's initial public offering (IPO) and were allocated through offline placement [5] - The company completed its IPO on May 16, 2025, with a total share capital of 88,000,000 shares, of which 71,459,253 shares are restricted [5] - The lock-up period for these restricted shares was six months from the IPO date [7] Group 2: Compliance and Commitments - All shareholders of the restricted shares have adhered to their commitments regarding the lock-up period [7][8] - The underwriter, CITIC Securities Co., Ltd., confirmed that the company has complied with relevant regulations regarding the listing of these shares [8][9] - There have been no changes in the company's share capital due to profit distribution or other factors since the formation of the restricted shares [6]

证券代码：688755 证券简称：汉邦科技 公告编号：2025-039 江苏汉邦科技股份有限公司 首次公开发行网下配售限售股份上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 1,059,253股。 本次股票上市流通总数为1,059,253股。 本次股票上市流通日期为2025 年 11 月 17 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2025 年 3 月 4 日出具的《关于同意江苏汉邦科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2025〕396 号），江苏汉邦科技股份有限公司（以下简称"公司"） 获准首次公开发行人民币普通股（A 股）2,200.00 万股，并于 2025 年 5 月 16 日 在上海证券交易所科创板上市。公司首次公开发行股票完成后，总股本为 88,000,000 股，其中有限售条件流通股 71,459,253 股，占公司总股本的 81.20%， 无 ...

中信证券股份有限公司 关于江苏汉邦科技股份有限公司 首次公开发行网下配售限售股份上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏汉 邦科技股份有限公司（以下简称"汉邦科技"或"公司"）首次公开发行股票和 持续督导工作的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就汉邦科技首 次公开发行网下配售限售股份上市流通的事项进行了专项核查： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2025 年 3 月 4日出具的《关于同意江苏汉邦科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2025〕396 号），公司获准首次向社会公开发行人民币普通股（A 股）2,200.00 万股，并于 2025 年 5 月 16 日在上海证券交易所科创板上市。公司 首次公开发行股票完成后，总股本为 88,000,000 股，其中有限售条件流通股 71,459,253 股，占公司总股本的 81.20%，无限售条件流通股 16,540,747 股，占公 司总股本的 18.80%。 本次上 ...

Core Viewpoint - Hanbang Technology is a leading enterprise in the field of chromatography purification equipment in China, focusing on providing specialized separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] Group 1: Business Performance - In Q3 2025, Hanbang Technology achieved a revenue of 506 million yuan, ranking 23rd out of 42 in the industry, with the industry leader Mindray Medical generating 25.834 billion yuan [2] - The net profit for the same period was 37.017 million yuan, placing the company 25th in the industry, while the top performer, Mindray Medical, reported a net profit of 7.814 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Hanbang Technology's debt-to-asset ratio was 34.37%, higher than the industry average of 27.21% [3] - The company's gross profit margin was 38.45%, down from 43.30% year-on-year, and below the industry average of 48.67% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.31% to 8,687, while the average number of circulating A-shares held per shareholder increased by 7.89% to 1,904.08 [5] - The top ten circulating shareholders saw a change, with Dongfanghong Medical Upgrade Stock Initiation A (015052) exiting the list [5] Group 4: Market Outlook - The small molecule liquid chromatography equipment market in China is expected to continue growing, projected to reach 5.2 billion yuan by 2027, with production-level small molecule liquid chromatography systems anticipated to reach 1.87 billion yuan by the same year [5] - Hanbang Technology possesses a differentiated competitive advantage in technology and has established a comprehensive product matrix for chromatography equipment [5] - Earnings per share are projected to be 1.15 yuan and 1.35 yuan for 2025 and 2026, respectively, with corresponding valuations of 41 times and 35 times [5]

Core Viewpoint - Hanbang Technology experienced a slight decline in stock price, with a trading volume of 39.14 million yuan on October 29, 2023, indicating a net outflow in financing activities [1] Financing Summary - On October 29, Hanbang Technology had a financing buy-in amount of 2.85 million yuan and a financing repayment of 5.56 million yuan, resulting in a net financing buy-in of -2.71 million yuan [1] - As of October 29, the total financing and securities lending balance for Hanbang Technology was 77.34 million yuan, which accounts for 10.36% of its circulating market value [1] - There were no shares repaid or sold in the securities lending segment on the same day, with a remaining balance of 0.00 yuan [1] Business Performance Summary - As of September 30, 2023, Hanbang Technology had 8,687 shareholders, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% to 1,904 shares [2] - For the period from January to September 2023, Hanbang Technology reported a revenue of 506 million yuan, representing a year-on-year growth of 4.61%, while the net profit attributable to shareholders decreased by 17.27% to 37.02 million yuan [2] - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [2] Company Overview - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province, and specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of Hanbang Technology includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]